Datamonitor, Nov 2011, Pages: 48
10-year epidemiology forecast of non-smallcelllungcancer.
- Understand the key epidemiologic risk factors associated with non-smallcelllungcancer.
Highlights
- Most people are not diagnosed
Timely Data Resources, Inc., Dec 2011, Pages: 15
websites. Sources and references are provided. The LungCancer Disease and Therapy Review provides an overview of small cell and non-smallcelllungcancer, with incidence, prevalence, and mortality
Decision Resources, Inc., April 2011, Pages: 29
and Challenges
-- Melanoma
-- Non-Small-CellLungCancer
-- Breast Cancer
2010 and Market Outlook
- Market Statistics
- Market Drivers and Constraints
About the Author - Abbott Laboratories
- Amgen
Future Medicine Ltd, Aug 2010, Pages: 92
in head and neck cancer, gene mutation in colorectal and non-smallcelllungcancer, and epigenetic aberrations. EDITORIAL:
- Today’s discoveries to tomorrow’s care: cancer biomarkers revisited
CJ Rosser
Business Insights, June 2011, Pages: 187
covered include: breast cancer; colon cancer; prostate cancer; non-smallcelllungcancer; melanoma; and renal cancer. This report reviews the direction of research, and key issues facing the industry
Informa Healthcare, May 2007, Pages: 280
. Epidermal Growth Factor Receptor Inhibition in Non-SmallCellLungCancer. Epidermal Growth Factor Receptor Targeted Therapy-Markers of Sensitivity and Response. Other Novel Targeted Therapies in LungCancer
Expert Reviews Ltd, June 2011, Pages: 210
Wheeler, Keith L Black
- Non-small-celllung carcinoma vaccines in clinical trials
Antonio Rossi, et al
- Colorectal cancer vaccines in clinical trials
Frank M Speetjens, et al Vaccines in Clinical
Research Facts Ltd, Aug 2010, Pages: 50
for lungcancer. These companies have either developed or are in the process of developing tests for e.g.:
- Screening and Early Detection
- Differentiation of the Histological Sub-Classes of Non-SmallCell
Bioseeker, Oct 2010, Pages: 659
's Lymphoma
9.28 Non-SmallCellLungCancer
9.29 Oesophageal Cancer
9.30 Osteo Sarcoma
9.31 Ovarian Cancer
9.32 Pancreatic Cancer
9.33 Prostate Cancer
9.34 Renal Cancer
9.35 Skin Cancer (general)
9
Espicom Business Intelligence Ltd, Sep 2007
development. These products look set to target some of the "big" cancers, with launches for vaccines against renal cell carcinoma, melanoma, prostate, non-smallcelllung and colorectal cancer
Espicom Business Intelligence Ltd, Sep 2007, Pages: 184
development. These products look set to target some of the "big" cancers, with launches for vaccines against renal cell carcinoma, melanoma, prostate, non-smallcelllung and colorectal cancer
Decision Resources, Inc., June 2007, Pages: 36
company continues to develop a biomarker test already shown to predict non-small-celllungcancer with 85% accuracy? Which other companies have clinical results forthcoming for a potential biomarker
Decision Resources, Inc., Dec 2008, Pages: 33
in non-small-celllungcancer be as successful?
- HER2 protein expression is commonly detected using technologies such as immunochemistry (IHC), fluorescence in situ hybridization (FISH), and chromogenic
Life Science Intelligence, Inc., Dec 2009, Pages: 1763
, endoscopy and catheterization on any scanner
- Molecular diagnostic tests to: 1-Differentiate between squamous and non-squamous non-small-celllungcancer, 2-Differentiate between mesothelioma
Sheila Greco Associates, May 2011, Pages: 1
pivotal trials underway in metastatic melanoma, in advanced primary liver cancer, and in non-smallcelllungcancer. In addition, the agent is being studied in multiple Phase II trials, as well
GBI Research, Feb 2011, Pages: 209
Cancer
6.6.3 Non-SmallCellLungCancer (NSLC)
6.6.4 Breast Cancer
6.6.5 Colon Cancer
6.6.6 Melanoma
6.6.7 Ovarian Cancer
6.6.8 Prostate Cancer
7 Drug Discovery and Preclinical Molecules by Therapy
